Clinical trial design
melanoma
MELANOMA
We designed a phase 1/1b study of concurrent IT and IV nivolumab in melanoma patients with LMD. The study consists of two parts: an IT dose escalation portion and a dose expansion cohort at the maximum tolerated dose (MTD) (Fig. 